Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory, High Risk Hematologic Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03404193
What this trial is testing

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm+12 more
M.D. Anderson Cancer Center 235
Testing effectiveness (Phase 2)Looking for participantsNCT06802315
What this trial is testing

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myeloid Leukemia, Relapsed, AdultAcute Myeloid Leukemia RefractoryChronic Myeloid Leukemia - Accelerated Phase+1 more
University of Illinois at Chicago
Testing effectiveness (Phase 2)Study completedNCT01177735
What this trial is testing

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Arkansas 71
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Testing effectiveness (Phase 2)Study completedNCT02921061
What this trial is testing

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Who this might be right for
Mixed Phenotype Acute LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid Leukemia+4 more
Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)Study completedNCT03601078
What this trial is testing

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 312
Not applicableStudy completedNCT00716911
What this trial is testing

Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
City of Hope Medical Center 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04542824
What this trial is testing

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaPrimary Mediastinal Large B Cell Lymphoma+3 more
Genmab 78
Testing effectiveness (Phase 2)Study completedNCT00006265
What this trial is testing

Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Leukemia
Alliance for Clinical Trials in Oncology 60
Early research (Phase 1)WithdrawnNCT03506802
What this trial is testing

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Who this might be right for
HLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Plasma Cell Myeloma+1 more
Jonsson Comprehensive Cancer Center
Early research (Phase 1)WithdrawnNCT00521261
What this trial is testing

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)WithdrawnNCT05367401
What this trial is testing

Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT03150004
What this trial is testing

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Medical College of Wisconsin 53
Early research (Phase 1)Study completedNCT04981912
What this trial is testing

Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

Who this might be right for
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
University of California, San Diego 4
Testing effectiveness (Phase 2)Study completedNCT00002521
What this trial is testing

Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Temple University
Testing effectiveness (Phase 2)UnknownNCT03598179
What this trial is testing

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Who this might be right for
Lymphoma, B-CellLeukemia, B-cell
The First Affiliated Hospital with Nanjing Medical University 10
Testing effectiveness (Phase 2)Study completedNCT02019069
What this trial is testing

CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Adult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)+13 more
Rondeep Brar 11
Testing effectiveness (Phase 2)Looking for participantsNCT03670966
What this trial is testing

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in Remission+9 more
Fred Hutchinson Cancer Center 30
Early research (Phase 1)Looking for participantsNCT06501196
What this trial is testing

BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute+3 more
BlossomHill Therapeutics 170
Testing effectiveness (Phase 2)Study completedNCT00569010
What this trial is testing

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia
M.D. Anderson Cancer Center 36
Next Page
38